Global Cord Blood Corp (NYSE:CO) Short Interest Down 11.1% in November

Global Cord Blood Corp (NYSE:CO) saw a significant decline in short interest during the month of November. As of November 29th, there was short interest totalling 49,800 shares, a decline of 11.1% from the November 14th total of 56,000 shares. Based on an average daily trading volume, of 98,100 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the company are sold short.

Shares of NYSE CO traded up $0.05 during mid-day trading on Friday, reaching $4.57. 53,255 shares of the company traded hands, compared to its average volume of 65,655. Global Cord Blood has a fifty-two week low of $4.14 and a fifty-two week high of $7.73. The firm has a market cap of $549.41 million, a PE ratio of 10.04 and a beta of 0.15. The stock has a fifty day simple moving average of $4.75 and a 200-day simple moving average of $5.26.

Global Cord Blood (NYSE:CO) last posted its quarterly earnings data on Tuesday, November 26th. The medical research company reported $0.14 EPS for the quarter. Global Cord Blood had a net margin of 34.86% and a return on equity of 10.88%. The business had revenue of $43.86 million for the quarter.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Global Cord Blood by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,826,896 shares of the medical research company’s stock worth $16,339,000 after buying an additional 29,396 shares during the last quarter. Man Group plc grew its position in Global Cord Blood by 0.9% in the third quarter. Man Group plc now owns 908,051 shares of the medical research company’s stock worth $4,395,000 after buying an additional 8,410 shares during the last quarter. Quinn Opportunity Partners LLC grew its position in Global Cord Blood by 2.3% in the second quarter. Quinn Opportunity Partners LLC now owns 259,764 shares of the medical research company’s stock worth $1,501,000 after buying an additional 5,800 shares during the last quarter. SG Americas Securities LLC grew its position in Global Cord Blood by 24.4% in the second quarter. SG Americas Securities LLC now owns 134,310 shares of the medical research company’s stock worth $776,000 after buying an additional 26,379 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in Global Cord Blood by 20.3% in the second quarter. Parametric Portfolio Associates LLC now owns 94,469 shares of the medical research company’s stock worth $546,000 after buying an additional 15,934 shares during the last quarter. Institutional investors and hedge funds own 16.27% of the company’s stock.

A number of research firms have recently weighed in on CO. TheStreet cut Global Cord Blood from a “b-” rating to a “c+” rating in a report on Wednesday, September 4th. ValuEngine upgraded shares of Global Cord Blood from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

Read More: P/E Growth (PEG)

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.